Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa

NACompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

June 19, 2025

Study Completion Date

June 19, 2025

Conditions
HIV/AIDSTuberculosis
Interventions
OTHER

TUTT-PT Intervention

All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.

Trial Locations (1)

1864

Perinatal HIV Research Unit, Soweto

All Listed Sponsors
collaborator

University of Witwatersrand, South Africa

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins University

OTHER

NCT06739915 - Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa | Biotech Hunter | Biotech Hunter